41st week of 2011 patent applcation highlights part 31 |
Patent application number | Title | Published |
20110250121 | AMMONIA SALTS AS REGENERABLE CO2 SORBENTS - The present method describes the absorbing and desorbing of a gaseous reactant on a solid reactant. The solid reactant is an ammonia salt selected from the group consisting of alkali ammonium salts, alkali ammonium earth salts or a combination thereof. | 2011-10-13 |
20110250122 | Core-Shell Nanocatalyst For High Temperature Reactions - The present invention provides a core-shell nanoparticle that includes a metal-oxide shell and a nanoparticle. Pores extend from an outer surface to an inner surface of the shell. The inner surface of the shell forms a void, which is filled by the nanoparticle. The pores allow gas to transfer from outside the shell to a surface of the nanoparticle. The present invention also provides a method of making a core-shell nanoparticle includes forming a metal-oxide shell on a colloidal nanoparticle, which forms a precursor core-shell nanoparticle. A capping agent is removed from the precursor core-shell nanoparticle, which produces the core-shell nanoparticle. The present invention also provides a method of using a nanocatalyst of the present invention includes providing the nanocatalyst, which is the core-shell nanoparticle. Reactants are introduced in a vicinity of the nanocatalyst, which produces a reaction that is facilitated or enhanced by the nanocatalyst. | 2011-10-13 |
20110250123 | Methods and apparatus for producing the halogen dioxide, chlorine dioxide, by ion exchange - The halogen dioxide, chlorine dioxide is produced from its chlorite reactant using ion exchange media in a stable reactant form, and then passing a known concentration of counter ions through the ion exchange media in a moist environment so that there is an exchange of ions, and the reactants that are released form activated chlorine dioxide within the ion exchange material. The ion exchange media both contributes reactants to and extracts contaminants from the moist environment via its ion exchange mechanism. The counter ions may be derived from one or more stable precursor solutions which themselves may contain reactants and/or soluble catalysts. The reactants of the precursor solutions cannot act as the counter ion, or ions, in the ion exchange mechanism, but the soluble catalysts can. The ion exchange media can be mixed or layered with one or more insoluble catalysts, to enhance the formation of the activated halogen dioxide, chlorine dioxide within the ion exchange material. | 2011-10-13 |
20110250124 | CATALYST FOR THE OXIDATION OF SO2 TO SO3 - The invention relates to a catalyst for the oxidation of SO | 2011-10-13 |
20110250125 | DEVICE, SYSTEM, AND METHOD FOR AN ADVANCED OXIDATION PROCESS USING PHOTOHYDROIONIZATION - A device, system, and method, for the formation of advanced oxidation products by contacting a hydrated catalytic surface of a catalytic target structure with broad spectrum ultraviolet light in the 100 nm to 300 nm range that preferably includes 185 nm and 254 nm wavelengths. The catalytic surface reacts with the ultraviolet light energy and hydrate at the catalytic surface to form advanced oxidation products, The catalytic surface in one embodiment includes a hydrophilic agent, titanium dioxide, silver, copper, and rhodium. Preferably, the catalytic surface is coated with a coating that includes the hydrophilic; agent, titanium dioxide, silver, copper, and rhodium. A photohydroionization cell ( | 2011-10-13 |
20110250126 | GROUP 4 METAL PRECURSORS FOR METAL-CONTAINING FILMS - The present invention is related to a family of Group 4 metal precursors represented by the formula: | 2011-10-13 |
20110250127 | TRANSITION METAL/ZEOLITE SCR CATALYSTS - A method of converting nitrogen oxides in a gas to nitrogen by contacting the nitrogen oxides with a nitrogenous reducing agent in the presence of a zeolite catalyst containing at least one transition metal, wherein the zeolite is a small pore zeolite containing a maximum ring size of eight tetrahedral atoms, wherein the at least one transition metal is selected from the group consisting of Cr, Mn, Fe, Co, Ce, Ni, Cu, Zn, Ga, Mo, Ru, Rh, Pd, Ag, In, Sn, Re, Ir and Pt. | 2011-10-13 |
20110250128 | Method for tissue characterization based on beta radiation and coincident Cherenkov radiation of a radiotracer - A method of characterizing a tissue sample is provided that includes injecting a tissue sample with radiotracers, where the radiotracers include beta-emitter radio tracers, the beta-emitter radio tracers emit beta particles according to a decay of the beta-emitter radio tracers, and measuring the beta particles or Cherenkov radiation from the beta particles in the tissue sample, and determining a condition of the radio tracers in the tissue sample according to the measured beta particles or the measured Cherenkov radiation, where the determined condition includes a depth and/or a concentration of the radiotracers in the tissue sample. | 2011-10-13 |
20110250129 | BIOLUMINESCENCE IMAGING-BASED SCREENING ASSAY AND INHIBITORS OF ABCG2 - A bioluminescence imaging-based high-throughput assay for inhibitors of ABCG2 is described. Compositions of inhibitors of ABCG2 and methods of using ABCG2 inhibitors are also described. | 2011-10-13 |
20110250130 | TNF-ALPHA BINDING PROTEINS - Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-α), e.g., human TNF-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies. | 2011-10-13 |
20110250131 | Antigens Associated with Endometriosis, Psoriatic Arthritis and Psoriasis - Specific binding members that bind the ED-A isoform of fibronectin for use in methods of diagnosis, detection, imaging and/or treatment of endometriosis, and/or for use in delivery to the neovasculature of endometriotic tissue of a molecule conjugated to the specific binding member. Specific binding members that bind tenascin-C, especially the A1, A2, A3, A4 and/or D domain tenascin-C large isoform, for use in methods of diagnosis, detection, imaging and/or treatment of endometriosis, psoriatic arthritis or psoriasis, and/or for use in delivery to the neovasculature of endometriotic, psoriatic arthritic or psoriatic tissue of a molecule conjugated to the specific binding member. | 2011-10-13 |
20110250132 | LIPOIC ACID METABOLITE: USEFUL FOR DRUG CARRIER, NANOPARTICLE CONJUGATE, IMAGING AND HYPERTHERMIA THERAPY - The present invention relates to simultaneous tracking or imaging followed by hyperthermia therapy for cancer and other diseases associated with altered metabolic enzymes. In particular, the invention relates to a novel class of therapeutic nanomaterial which selectively target and kill tumor cells. | 2011-10-13 |
20110250133 | GASTRIN RELEASING PEPTIDE COMPOUNDS - Methods and compositions for diagnosing, staging disease, monitoring therapeutic effect of drugs and imaging a patient are provided, including radiopharmaceutical formulations. Compositions comprising Ga-AMBA complexed with a radioactive isotope are provided; as are methods of imaging Gastrin Releasing Peptide receptor (GRP-R) bearing tissue and methods of diagnosing or staging disease in patients suspected of having disease associated with aberrant GRP-R function. Further, methods of monitoring therapeutic effect of a drug targeted to a receptor that crosstalks with GRP-R are provided; as are methods of pre-dosing/co-dosing non-target tissues containing GRP-R. Particularly, methods of monitoring activity of receptors and receptor pathways in vivo/in vitro by using a ligand that binds to the GRP-R are provided; as are methods of measuring the activity of a receptor or group of receptors and their associated pathways that exhibit crosstalk with the GRP-R by using such a ligand which is also detectable by external means. | 2011-10-13 |
20110250134 | SUSTAINED RELEASE NITRIC OXIDE FROM LONG LIVED CIRCULATING NANOPARTICLES - The invention provides methods for delivering a NO molecule or precursor thereof to a vascular compartment of a subject comprising: administering to the subject, a NO particle formulation, via an intravascular, intraperitoneal, or intramuscular administration, in an amount sufficient to induce vascular smooth muscle relaxation thereby delivering the NO molecule or precursor thereof to the vascular compartment of the subject, wherein the NO particle formulation comprises NO attached to a nanoparticle or microparticle. | 2011-10-13 |
20110250135 | Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use - The invention relates to compounds of formula I, their synthesis and their use, in particular for detecting amyloid deposits in a patient. | 2011-10-13 |
20110250136 | FLUORINATED BENZOTHIAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND IMAGING AGENT FOR DIAGNOSING ALTZHEIMER'S DISEASE USING THE SAME - The present invention relates to fluorinated benzothiazole derivatives, a preparation method thereof, and an imaging agent for diagnosing Alzheimer's disease using the same, and more particularly to fluorinated benzothiazole derivatives represented by Chemical Formula 1, derivatives of Chemical Formula 2 as a starting material for preparation thereof, a preparation method thereof, and an imaging agent for diagnosing Alzheimer's disease using fluorinated benzothiazole derivatives with a strong binding force to beta-amyloid plaque, which is a kind of biomarker for Alzheimer's disease. According to the present invention, fluorine-labeled benzothiazole derivatives, which have been difficult to synthesize by conventional methods, may be obtained by simple processes and the thus-obtained benzothiazole derivatives may be useful in diagnosing the presence and severity of Alzheimer's disease. | 2011-10-13 |
20110250137 | RADIOISOTOPE-LABELED LYSINE AND ORNITHINE DERIVATIVES, THEIR USE AND PROCESSES FOR THEIR PREPARATION - The invention relates to the compounds suitable for radiolabeling with a chelator free radioisotope and radiolabeled compounds of the general Formula I. | 2011-10-13 |
20110250138 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A METAL-CHELATING LIGAND - The invention provides modified oligonucleotides of formula (I), comprising at least one metal chelator which provides a powerful tool for study of the pharmacokinetics of siRNA and its correlation with in vivo activity. The chelated metals provide luminescent properties enable detection of the oligonucleotides through the use of time-resolved fluorescent quenching based on energy transfer from the metal ion to a nonfluorescent quencher which can be used as non-isotopic labels of oligonucleotides for diagnostics and evaluation of cellular uptake. | 2011-10-13 |
20110250139 | Modified Pyrazine Derivatives and Uses Thereof - Provided herein are compounds, preparations and formulations comprising pyrazine derivatives having multiple poly(ethylene glycol) containing substituents. Many of the compounds disclosed herein are excretable by the renal system of a subject or patient and are useful for visualizing the renal system of a subject or patient. Upon excitation by electromagnetic radiation, a number of the compounds disclosed herein exhibit luminescence and are externally detectable when present in the body fluid of a patient or subject. Also provided herein are methods for visualizing the renal system of a subject or patient. | 2011-10-13 |
20110250140 | Modified Pyrazine Derivatives and Uses Thereof - In some embodiments, the invention provides modified pyrazine derivatives containing a central pyrazine ring with two secondary amine groups attached directly to the central pyrazine ring and two amino carbonyl groups attached directly to the central pyrazine ring. The secondary amine groups are terminated by alkyl groups containing from 1 to 6 carbons. The amino carbonyl groups can be terminated by a wide range of substituents including, but not limited to, alkyl and alkylene groups, polyether groups, including poly(ethylene glycol) groups, secondary and tertiary amine groups, polyhydroxylated alkyl groups, amino carbonyl groups, amino thioketone groups, and combinations thereof. In some embodiments, the invention provides modified pyrazine derivatives useful as optical agents in a wide variety of biomedical imaging procedures, including diagnostic and imaging procedures. In an embodiment, for example, modified pyrazine derivatives are provided which are useful in monitoring organ and system functioning, for example in monitoring renal system functioning. | 2011-10-13 |
20110250141 | Methods For Improving Skin Quality - A skin treatment regimen for delivery of a rinse-off personal skin care composition is provided. The rinse-off personal skin care composition includes varying ratios of a lathering agent to a hydrophobic benefit agent. The rinse-off personal skin care composition can be applied to skin of a user in phases over and/or in a treatment cycle. Each of the phases of the treatment cycle can include a ratio of the varying ratios that can be different such as higher or lower than a ratio of adjacent phase. | 2011-10-13 |
20110250142 | COMBINATION THERAPIES FOR TREATMENT OF HYPERTENSION AND COMPLICATIONS IN PATIENTS WITH DIABETES OR METABOLIC SYNDROME - Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and a second antihypertensive agent (preferably a calcium antagonist, an ACE inhibitor, or an angiotensin II receptor antagonist) for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome. | 2011-10-13 |
20110250143 | PROCESS FOR PREPARING CHLORINS AND THEIR PHARMACEUTICAL USES - The disclosed subject matter includes methods of preparation, properties, pharmaceutical compositions and methods of therapy of sulfonated chlorins and bacterioclorins designed for the photodynamic therapy (PDT) of hyperproliferative tissues such as tumors, hyperproliferative blood vessels and other disorders or abnormalities that are responsive to PDT. In particular, the economical large-scale synthesis of stable chlorins and bacteriochlorins is described. Their properties were tailored to meet those of ideal photosensitizers for PDT. In another embodiment, pharmaceutical compositions and methods of therapy for systemic administration are provided. In a further embodiment, pharmaceutical compositions and methods of therapy for topical administration are also provided. Further provided is a method of labeling a target tissue and providing an image of that tissue by fluorescence of magnetic resonance imaging. | 2011-10-13 |
20110250144 | RGD-CONTAINING PEPTIDOMIMETICS AND USES THEREOF - The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radio imaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for in targeted chemotherapy. | 2011-10-13 |
20110250145 | BIOLUMINESCENCE IMAGING OF MYELOPEROXIDASE ACTIVITY IN VIVO, METHODS, COMPOSITIONS AND APPARATUSES THEREFOR - Methods of imaging distribution of myeloperoxidase activity in a subject are disclosed. These methods include the use of bioluminescent substrates, including luminol and wavelength-shifted analogues of luminol. Bioluminescent myeloperoxidase substrates that emit light at longer wavelengths compared to luminol are shown to be useful for imaging myeloperoxidase activity in vivo. The disclosed methods can be used for imaging sites of inflammation and other pathological conditions associated with abnormal levels of MPO activity in vivo. Methods of synthesis of luminol analogues are also disclosed. | 2011-10-13 |
20110250146 | MAGNETIC NANOPARTICLE AND METHOD FOR IMAGING T CELLS - The present invention provides nanoparticles having a core comprising a magnetic material and having a surface, where the surface may be operatively linked to an antigenic peptide-major histocompatibility complex (MHC) monomer. The antigenic peptide-MHC monomer may then be recognized by a T cell receptor. These nanoparticles may further comprise a signal-generating label, such as a fluorophore. Methods employing nanoparticles of the present invention may involve magnetic resonance imaging and/or fluorescence detection, such that cell imaging and localization are performed. | 2011-10-13 |
20110250147 | Method and System for Reducing Skin Friction - A film forming material can be used for the preparation of a medicament for pre-treating an area of skin to reduce causes of skin irritation, resulting in a educed risk of acquiring skin chafing and/or blisters. A method of pre-treating can comprise the steps of: providing a dispensing device containing a film forming material; and applying a film forming material to an area of skin, for pre-treating an area of skin to reduce friction and thereby reduce the risk of acquiring chafing and/or a blister. | 2011-10-13 |
20110250148 | COLD PROCESS WATER SOLUBLE WAX CONTAINING POWDERS - Inventive subject matter described herein includes a powder comprising: a wax having a melt point within a range of 45 to 100 degrees Centigrade and sodium polyacrylate or salts of sodium polyacrylate or sodium polyacrylate and salts of sodium polyacrylate wherein the wax concentration falls within a range of 99.9% to 0.1% by weight and the sodium polyacrylate concentration falls within a range of 0.1% to 99.9% by weight, wherein the powder is effective for forming a cream or lotion or gel or coating when mixed with water at room temperature or cooler than room temperature. | 2011-10-13 |
20110250150 | Multi-Part Kit Comprising A Chewing Gum And Further A Flavor Containing Formulation - A multi-part kit for administering at least one active pharmaceutical ingredient including at least one piece of chewing gum including the active pharmaceutical ingredient, the piece of chewing gum comprising gum base; and at least one further flavor-containing formulation; wherein the gum base content of the at least one further flavor-containing formulation is less than 70% by weight of the gum base content of said piece of chewing gum. | 2011-10-13 |
20110250151 | COLD PROCESS WATER SOLUBLE WAX CONTAINING POWDERS - Inventive subject matter described herein includes a powder comprising: a wax having a melt point within a range of 45 to 100 degrees Centigrade and sodium polyacrylate or salts of sodium polyacrylate or sodium polyacrylate and salts of sodium polyacrylate wherein the wax concentration falls within a range of 99.9% to 0.1% by weight and the sodium polyacrylate concentration falls within a range of 0.1% to 99.9% by weight, wherein the powder is effective for forming a cream or lotion or gel or coating when mixed with water at room temperature or cooler than room temperature. | 2011-10-13 |
20110250152 | Anti-Microbial Dental Formulations for the Prevention and Treatment of Oral Mucosal Disease - Compositions and methods are directed to antimicrobial compositions and articles that release .NO from the composition and/or article in an amount effective to prevent gingival and other oral mucosal diseases. | 2011-10-13 |
20110250153 | OLIGOMERIC BIOSURFACTANTS IN DERMATOCOSMETIC COMPOSITIONS - Oligomeric acylated biosurfactants (“OABs”) having low critical micelle concentrations of from about 1.0 ppm to about 200 ppm, preferably less than about 50 ppm, in an aqueous solution of Minimal Essential Media that can lower the surface tension in the aqueous MEM environment to less than about 50 dynes/cm | 2011-10-13 |
20110250154 | COSMETIC COMPOSITIONS COMPRISING POLYHYDROXYLTATE FATTY ALCOHOLS AND DERIVATIVES AND USES THEREOF - Cosmetic methods and compositions for preventing or reversing damage caused to the skin of a subject by environmental pollution and/or UV radiation, the methods and compositions comprising isolated polyhydroxylated fatty alcohols or derivatives thereof for topical application, in an amount effective to prevent or reverse the harmful effects of environmental pollution and/or UV radiation on the skin e.g. by reducing the damage to the skin cells and/or improving the aesthetic appearance of human skin. | 2011-10-13 |
20110250155 | HYDROXYPROPYL METHYLCELLULOSE-CONTAINING SUNSCREEN COMPOSITIONS AND METHODS OF USE - Described are sunscreen compositions, composing inorganic metal oxide sunscreen particles and hydroxypropyl methylcellulose, and methods of boosting the SPF (sun protection factor) of a sunscreen composition having inorganic metal oxide sunscreen particles, comprising including hydroxypropyl methylcellulose with a DS | 2011-10-13 |
20110250156 | POLYAMIDE 10.10 POWDER AND ITS USE IN PERSONAL CARE PRODUCTS - The present invention is directed to particles based on polyamide 10.10, wherein the particles have a mean particle size d | 2011-10-13 |
20110250157 | Skin Hyperpigmentation Acyl Glutathione Treatments - Topical compositions for treatment of hyperpigmentation comprise an effective amount of S-acyl glutathione derivative and a carrier. Methods for treating hyperpigmentation, such as melasma, postinflammatory hyperpigmentation and lentigines, skin lightening and skin whitening comprise applying a composition containing S-acyl glutathione derivative in a dermatologically acceptable carrier to skin tissue. The acyl group is a saturated or unsaturated aliphatic C | 2011-10-13 |
20110250158 | CYCLOHEXYLETHYL CARBOXYLIC ACID ESTER COMPOSITIONS AND METHOD FOR USING THE SAME FOR REDUCING MALODORS - The present invention pertains to a method of counteracting a malodor by introducing a malodor counteracting effective amount of an enantiomeric compound selected from the group consisting of (1R)-1-cyclohexylethyl butyrate and (1S)-1-cyclohexylethyl acetate. | 2011-10-13 |
20110250159 | CYCLOHEXYLETHYL CARBOXYLIC ACID ESTER COMPOSITIONS AND METHOD FOR USING THE SAME FOR REDUCING MALODORS - The present invention pertains to a method of counteracting a malodor by introducing a malodor counteracting effective amount of an enantiomeric compound selected from the group consisting of (1R)-1-cyclohexylethyl butyrate and (1S)-1-cyclohexylethyl acetate. | 2011-10-13 |
20110250160 | TRANSPARENT ANTIPERSPIRANT GELS - The present invention relates to transparent antiperspirant compositions in the form of a water-in-oil emulsion, which contain a balanced mixture of selected oil components and emulsifiers in order to improve the antiperspirant effect. | 2011-10-13 |
20110250161 | VEGETABLE BASED THREE COMPONENT HAIR RELAXER - The disclosure relates to a three part, vegetable-based, no-lye composition for relaxing human hair that excludes petroleum derived raw materials. The disclosure relates to a cream base, a hydroxide cream dispersion, and an aqueous activator solution. The disclosure further relates to methods for relaxing human hair with minimal damage to the hair and improved performance compared to existing no-lye relaxer products. | 2011-10-13 |
20110250162 | DISINFECTING AND DETOXIFYING META-ARAMID PARTICLES - Porous, permeable particles of meta-aramid can be chlorinated or brominated to produce antimicrobial and detoxifying particles for use in applications such as, but not limited to, nonwoven webs, paper, textiles, absorbent articles, healthcare products, paints, filter materials, powder coatings, clear coatings, molded plastic articles, binders for fibrous materials, and the like. The particles can be charged with halogen before or after incorporation into the application medium. The particles can contain blends of meta-aramid with other polymers such as, but not limited to, cellulose, cellulose acetate, polyurethane, and the like. The particles will be effective at inactivation of pathogenic and odor-causing microorganisms and toxic chemical agents. The particles, which contain N-halamine units, have unexpected resistance to ultraviolet light degradation. | 2011-10-13 |
20110250163 | MONO- AND DI-PEG IL-10 PRODUCTION; AND USES - Provided are methods of producing a mixture of mono- and di-pegylated IL-IO. | 2011-10-13 |
20110250164 | Antimicrobial Copolymer for Coating Surfaces, Obtained by Derivatization of a Vinylamine-Vinylalcohol Copolymer - A composition including the reaction product of at least a vinylamine-vinyl alcohol copolymer; an epoxyalkane; and a fluorocarbon that includes a reactive portion capable of reacting with the vinylamine-vinyl alcohol copolymer. Articles including coatings of such compositions, methods of preparing antimicrobial water-repellant surfaces and methods of preparing an antimicrobial water-repellant composition are also included. | 2011-10-13 |
20110250165 | Antibodies against CXCR4 and Methods of Use Thereof - The invention provides human monoclonal antibodies, scFv antibodies, scFv-Fc fusions, a dAb (domain antibodies), F | 2011-10-13 |
20110250166 | COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER - The present invention relates to a combined preparation comprising at least one rocaglamide derivative and at least one apoptosis inducing agent, preferably from the group of substances comprising agents inducing the extrinsic apoptotic pathway, antiproliferative agents and agents which induce apoptosis in T-cells by activation induced cell death (AICD) for the treatment of cancer. | 2011-10-13 |
20110250167 | METHOD FOR PURIFYING PROTEINS - The present invention provides methods and kits for purifying a target protein group. The method comprises the steps of contacting a sample comprising at least 95% of the target protein group and at most 5% of contaminating proteins with a library of binding moieties having different binding moieties, binding the contaminating proteins and a minority of the target protein group to the library of binding moieties, separating the unbound target protein group from the proteins bound to the library of binding moieties and collecting the unbound target protein. The collected target protein is more pure than the target protein group in the sample. | 2011-10-13 |
20110250168 | Sialoadhesin-related compositions and methods - Methods of delivering a cargo moiety to a cell is provided according to embodiments of the invention which includes contacting a cell expressing sialoadhesin with a conjugate including a sialoadhesin binding moiety and a cargo moiety. The sialoadhesin binding moiety binds to the sialoadhesin expressed by the cell and is internalized along with the cargo, delivering the cargo moiety to the cell. Particular methods provided by the invention include induction or enhancement of sialoadhesin expression in a cell which naturally produces little or no sialoadhesin. Induction or enhancement of sialoadhesin expression includes transfection of a sialoadhesin expression construct and/or administration of an agent effective to induce or enhance sialoadhesin expression. Methods and compositions for stimulating an immune response in a subject are detailed. Particular methods and compositions for stimulating an immune response to a virus are provided by the invention. | 2011-10-13 |
20110250169 | DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS - The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. | 2011-10-13 |
20110250170 | Immunocytokines for Tumour Therapy with Chemotherapeutic Agents - Immunocytokine comprising cytokine, e.g. interleukin 2 (IL-2), conjugated to antibody against tumour neovasculature antigen, e.g. tenascin-C, for use in combination therapy with chemotherapeutic agent such as temozolomide. Use of immunocytokine and chemotherapy for treatment of tumours e.g. glioblastoma and other cancers. | 2011-10-13 |
20110250171 | Compositions and Methods for Cancer Immunotherapy - The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer. | 2011-10-13 |
20110250172 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2011-10-13 |
20110250173 | Methods and compositions for inhibition of Treg cells - The present invention relates to methods of suppressing the immune tolerance of a disease or disease antigens in a patient. The method also promotes the activity of the effector T lymphocytes. The invention includes administering a therapeutic composition that promotes a Th1 environment in the patient while decreasing the immunosuppressive activity of Treg cells that can lead to disease antigen tolerance and immunoavoidance of the disease antigens by the patient. The therapeutic composition includes allogeneic emTh-1 cells. The therapeutic composition can also include disease antigens such as the chaperone-rich cell lysate of the disease antigen. | 2011-10-13 |
20110250174 | STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC HETEROCOMPLEXES - The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterised in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond. | 2011-10-13 |
20110250175 | TLR7 LIGAND AND USES THEREOF - The present invention provides a TLR7 ligand and its use in therapeutic applications. Specifically, the present application provides a RNA oligonucleotide comprising a G:U wobble base pair in the context of a fully double-stranded structure and its use in treating disease such as viral infections, immune disorders and cancer. | 2011-10-13 |
20110250176 | Combinations of Hepatitis C Virus Inhibitors - The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating Hepatitis C using such combinations. | 2011-10-13 |
20110250177 | ALPHA INTERFERON VARIANTS - The present invention provides biologically active variants of human α-2b-interferon. The variants contain carboxy terminus truncations when compared with the amino acid sequence of full-length human α-2b-interferon. It is the novel finding of the present invention that these truncated variants have the biological activity of full-length human α-2b-interferon. The invention encompasses these biologically active variant α-interferons, as well as polynucleotides encoding these interferons. Expression cassettes comprising these polynucleotides and host cells comprising the expression cassettes are also provided. The invention also provides compositions comprising variant α-interferon polypeptides and a pharmaceutically acceptable carrier. | 2011-10-13 |
20110250178 | COSMETIC COMPOSITIONS COMPRISING MICROALGAL COMPONENTS - The invention provides cosmetic compositions comprising microalgal biomass, whole microalgal cells, and/or microalgal oil in combination with one or more other cosmetic ingredients, and methods of making such compositions. In preferred embodiments, the microalgal components of the cosmetic compositions are derived from microalgal cultures grown heterotrophically and which comprise at least 10% oil by dry weight. | 2011-10-13 |
20110250179 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER - The present invention relates to methods for the treatment of cancer based on the induction of the choline kinase beta (hereinafter ChoKβ) activity as well as to methods for the design of personalized therapies and for determining the response of an agent capable of inducing choline kinase beta (hereinafter ChoKβ) for the treatment of cancer as well as to methods for determining the prognosis of a patient based on the determination of the ChoKβ expression levels as well as based on the determination of the relationship between the ChoKβ and ChoKα expression levels. Finally, the invention relates to methods for determining the response of a patient who suffers from cancer to ChoKα-inhibiting agents based on the determination of the PEMT and/or ChoKβ expression levels. | 2011-10-13 |
20110250180 | CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE - The present invention provides a CCN3 peptide for treating a subject in need thereof having an amino acid sequence identified as CCNp37, CCNp38 (human), CCNp38 (mouse), a cysteine-substituted CCNp37, cysteine-substituted CCNp38 (human) or a cysteine-substituted CCNp38 (mouse). | 2011-10-13 |
20110250181 | HUMAN LYSOSOMAL PROTEINS FROM PLANT CELL CULTURE - A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases. | 2011-10-13 |
20110250182 | ANGIOGENESIS USING PLACENTAL STEM CELLS - Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells. | 2011-10-13 |
20110250183 | Combination Therapy for Treatment of Patients with Neurological Disorders and Cerebral Infarction - The present invention provides compositions and methods for treating stroke patients using TCM and a Western medicament used for the treatment of stroke patients. | 2011-10-13 |
20110250184 | METHODS FOR DETERMINING EFFICACY OF A THERAPEUTIC REGIMEN AGAINST DELETERIOUS EFFECTS OF CYTOTOXIC AGENTS IN HUMAN - The invention provides drug screening methods and methods for determining efficacy of a therapeutic regimen in humans. In particular, the invention provides screening methods to determine efficacy of a therapeutic regimen to protect human subjects from deleterious effects of cytotoxic agents. The inventive method comprises i) extracting target cells from the human subject prior to exposure to a cytotoxic agent, ii) treating the subject with a cytotoxic protective drug; iii) extracting the target cells from the subject after treatment with the cytotoxic protective drug of step ii); iv) exposing the target cells of steps i) and iii) to the cytotoxic agent; and v) analyzing and comparing one or more parameters indicative of viability and growth conditions in target cells of step i) and step iii), wherein a favorable viability and growth condition of the target cells of step iii) as compared to target cells of step i) is indicative of the efficacy of the therapeutic regimen in the human subject. | 2011-10-13 |
20110250185 | TUMOR SUPPRESSION USING PLACENTAL STEM CELLS - The present invention provides methods of suppression of tumor cell proliferation and tumor growth using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of tumor suppression, and compositions comprising such cells and cell populations. | 2011-10-13 |
20110250186 | METHODS FOR PROMOTING WOUND HEALING AND MUSCLE REGENERATION WITH THE CELL SIGNALING PROTEIN NELL1 - The present invention provides methods for promoting wound healing and treating muscle atrophy in a mammal in need. The method comprises administering to the mammal a Nell1 protein or a Nell1 nucleic acid molecule. | 2011-10-13 |
20110250187 | COMPOSITIONS AND METHODS FOR TREATING HYPOPHOSPHATASIA - The present invention provides compositions and methods for use in enzyme replacement therapy. The inventors disclose a method of producing membrane bound enzymes in an active soluble form by eliminating the glycosylphosphatidylinositol (GPI) membrane anchor. In particular the inventors disclose a soluble active form of the membrane bound enzyme TNSALP which they produced by deleting the GPI anchor single peptide sequence. They have further shown that this composition is useful for treatment of hypophosphatasia. The inventors also disclose oligo acid amino acid variants thereof which specifically target bone tissue. | 2011-10-13 |
20110250188 | LCMV-GP-VSV-Pseudotyped Vectors and Tumor-Infiltrating Virus-Producing Cells for the Therapy of Tumors - The invention relates to recombinant VSV viruses and viral vectors which produce a glycoprotein GP of the lymphocyte choriomeningitis virus (LCMV) instead of the G protein of the VSV, to virus producing cells which produce LCMV-GP-pseudotyped VSV virions, and to the use of said vectors and cells in the therapy of solid tumors, especially brain tumors. | 2011-10-13 |
20110250189 | T CELL APOPTOSIS INDUCER - An inducer of T cell apoptosis and a health food for inducing T cell apoptosis comprising as an active ingredient of a lactic acid bacterium belonging to the genus | 2011-10-13 |
20110250190 | PHARMACEUTICAL PREPARATION - The present invention relates to a pharmaceutical preparation for treating an inflammatory condition, preferably a condition associated with ischemia comprising: a) a physiological solution comprising peripheral blood mononuclear cells (PBM-Cs) or a subset thereof, or b) a supernatant of the solution a), wherein the solution a) is obtainable by cultivating PBMCs or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h. | 2011-10-13 |
20110250191 | COMPOSITION FOR ENHANCING PHYSICAL PERFORMANCE - This invention relates to a composition that contains quercetin, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin C, caffeine, epigallocatechin gallate, epicatechin, epicatechin gallate, and epigallocatechin. | 2011-10-13 |
20110250192 | USE OF MICRORNA SIGNATURES FOR ASSESSING RISK LEVELS OF NEUROBLASTOMA PATIENTS - Methods for assessing the risk level or survival/death probability of a neuroblastoma patient based on a number of microRNA signatures, optionally in combination with Dicer, Drosha, and age at diagnosis. Also disclosed herein is use of Dicer, Drosha, or both in suppressing neuroblastoma cell growth | 2011-10-13 |
20110250193 | COMPOSITION COMPRISING EXPRESSION OR ACTIVITY INHIBITORS OF NINJURIN1 FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE - The present invention relates to a composition comprising a Ninjurin1 expression or activity inhibitor for the prevention and treatment of inflammatory disease. Ninjurin1 protein is specifically expressed in macrophages around blood vessels, increases cell-cell adhesion and cell-matrix adhesion, increases expressions of Wnt7 | 2011-10-13 |
20110250194 | Treatment with Anti-ErbB2 Antibodies - The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient. | 2011-10-13 |
20110250195 | Antibodies Against IL-25 - The present invention relates to IL-25 antibody VH domains and target binding members (e.g., antibodies) that comprise such antibody VH domains and bind IL-25. The invention also relates to compositions comprising target binding members {e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease). | 2011-10-13 |
20110250196 | PHARMACEUTICAL COMPOSITION USING GONADOTROPIN - RELEASING HORMONE (GNRH) COMBINED VARIANTS AS IMMUNOGEN - A pharmaceutical composition using natural gonadotropin-releasing hormone (GnRH), and/or some of its mimetic peptides, indistinctly bound by its amino or carboxyl extremes to a carrier molecule; in one case by its carboxyl extreme and in the other case by the amino terminal extreme, thus eliciting a faster and more potent immunological response against the endogenous GnRH hormone. This finally leads to the ablation of the GnRH and consequently of the rest of the involved hormones in the stream GnRH/LH-FSH/Testosterone-(estrogens). An advantage of this formulation consists on facilitating the exposition to the immune system of a greater number of epitopes of the GnRH or its mimetics, minimizing thus the steric hindrance produced by the carriers. This invention has a direct application in the castration of pets and animals of economic interest, in the control of human fertility as well as in the treatment of hormone-sensitive tumors, such as that of the prostate, the breast, ovary, the endometry, testicles, hypophysis, salivary glands and other kinds of human tumors. | 2011-10-13 |
20110250197 | PHARMACEUTICAL COMBINATION - This invention relates to a combination product or medicament comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents, antihyperglycaemic agents, anti-inflammatory agents or mixture thereof. Also provided herein are the pharmaceutical compositions comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents, antihyperglycaemic agents, anti-inflammatory agents or mixture thereof and optionally together with at least one pharmaceutically acceptable carrier, and methods for the treatment or prophylaxis of cardiovascular diseases, Alzheimer's disease, obesity, diabetes or inflammatory diseases comprising administering to a mammal in need thereof therapeutically effective amounts of combination pharmaceutical composition comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents, antihyperglycaemic agents, anti-inflammatory agents or mixtures thereof. | 2011-10-13 |
20110250198 | ActRIIB FUSION POLYPEPTIDES AND USES THEREFOR - Methods and compositions for inhibiting growth and differentiation factor-8 (GDF-8) activity in vitro and in vivo are provided. The methods and composition can be used for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or glucose homeostasis. | 2011-10-13 |
20110250199 | IMMUNOTOXINS AND USES THEREOF - The invention provides novel recombinant immunotoxins comprising domain III of cholix toxin and exotoxin from | 2011-10-13 |
20110250200 | SOLUBLE LYMPHOTOXIN-BETA RECEPTOR FUSION PROTEIN AND METHODS FOR INHIBITING LYMPHOTOXIN BETA-RECEPTOR SIGNALING - This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided. | 2011-10-13 |
20110250201 | ANTAGONISTS OF IL-6 TO RAISE ALBUMIN AND/OR LOWER CRP - The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved. | 2011-10-13 |
20110250202 | REAGENTS, METHODS, AND SYSTEMS FOR DETECTING METHICILLIN-RESISTANT STAPHYLOCOCCUS - The present invention provides PBP2a peptide antigens for generating antibodies against MRSA, and provides high-affinity binding agents that detect MRSA by selective immunoreactivity with PBP2a. The antibodies are useful in methods and systems for detecting MRSA, including biosensor systems, or as components of diagnostic or detection kits. The antibodies, in some embodiments, have therapeutic value against MRSA infection. | 2011-10-13 |
20110250203 | ANTI-CD5 ANTIBODIES - The present invention relates to the field of compositions comprising anti-CD5 antibodies. In particular, the present invention concerns an antibody composition comprising at least two anti-CD5 antibodies capable of binding distinct CD5 epitopes. The invention further concerns bi-specific molecules having the binding specificities of said antibody compositions. The invention also relates topharmaceutical compositions, use of antibody compositions and methods for manufacturing antibody compositions. The invention further relates to cell banks and a method for killing cells. | 2011-10-13 |
20110250204 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING DISEASES - Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods. | 2011-10-13 |
20110250205 | ANTI-SCLEROSTIN ANTIBODIES - Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject. | 2011-10-13 |
20110250206 | MARKERS FOR DETERMINATION OF PATIENT RESPONSIVENESS - Compositions and methods are provided for prognostic classification of inflammatory diseases, e.g. inflammatory demyelinating disease, patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Assessment of this signature pattern thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is multiple sclerosis or neuromyelitis optica. | 2011-10-13 |
20110250207 | ANTI-FXI ANTIBODIES AND METHODS OF USE - Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use. | 2011-10-13 |
20110250208 | Oxidized Cardiolipin as a Novel Pro-Inflammatory Factor - Low levels of antibodies reactive with oxidised Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunisation and therapy of these diseases and conditions are provided. | 2011-10-13 |
20110250209 | INHIBITION OF PLGF TO TREAT PHILADELPHIA CHROMOSOME POSITIVE LEUKEMIA - The present application relates to the field of leukemias, and more in particular to how P1 GF inhibition can help to treat Philadelphia chromosome positive (Ph+) leukemias. Methods are provided for treating Ph+ leukemias by administering P1 GF inhibitors. Also disclosed are uses of P1 GF inhibitors in the treatment of Ph+ leukemias, or for the preparation of a medicament against Ph+ leukemias. | 2011-10-13 |
20110250210 | Neutralizing Antibodies and Fragments Thereof Directed Against Platelet Factor-4 Variant 1 (PF4V1) - The present invention relates to neutralizing antibodies and fragments thereof directed against Platelet Factor-4 variant 1 (PF4v1) and their use for treating pathologies that require induction of angiogenesis or diseases associated with pathological angiogenesis. | 2011-10-13 |
20110250211 | VARIABLE DOMAINS OF CAMELID HEAVY-CHAIN ANTIBODIES DIRECTED AGAINST GLIAL FIBRILLARY ACIDIC PROTEINS - The present invention relates to the use of variable domains of camelid heavy-chain antibodies (VHH domains) directed against an intracellular target and having an isoelectric point of at least 8.5, for targeting said intracellular target or for the preparation of a peptide vector. Particularly, it concerns VHH domains directed against a glial fibrillary acidic protein and uses thereof for preparing therapeutic or diagnostic agents. | 2011-10-13 |
20110250212 | THERAPY PROCEDURE FOR DRUG DELIVERY FOR TRIGEMINAL PAIN - The present invention relates to methods for the treatment or prevention of trigeminal nerve-associated pain, in particular chronic, acute and procedural-related pain. The methods comprise administration of analgesic agents to the trigeminal nerve system which results in analgesia to the facial or head region. | 2011-10-13 |
20110250213 | ANTIBODIES TO CD122 - The invention provides monoclonal antibodies that specifically bind to CD122, which is one component of receptors for IL-2 and IL-15. The monoclonal antibodies have the capacity for substantial inhibition of both IL-2 and IL-15 mediated functions by inhibiting binding of these cytokines to their receptors. The monoclonal antibodies can be used for inhibiting undesired immune responses or treatment of cancer, among other applications. | 2011-10-13 |
20110250214 | DRUG DELIVERY SYSTEM TOWARD DEMYELINATING LESION AND BIOCHEMICAL MARKER OF DEMYELINATING LESION - It is intended to provide a drug delivery system toward a demyelinating lesion. It is also intended to provide a biochemical marker of a demyelinating lesion. A delivery system for a prophylactic and/or therapeutic agent for a demyelinating disease characterized in that a substance capable of specifically recognizing Contactin is conjugated to an active ingredient of a prophylactic and/or therapeutic agent for a demyelinating disease is provided. Also provided is a method of evaluating and/or differentiating a demyelinating disease, including measuring the expression of Contactin in a body fluid. | 2011-10-13 |
20110250215 | STRUCTURALLY-RELATED RELAXIN-FUSION PROTEINS WITH EXTENDED IN VIVO HALF-LIVES - Disclosed are human relaxin-Fc fusion proteins having an increased serum half-life, polynucleotides encoding the same, and intermediates formed during the fusion protein biosynthesis. The fusion proteins may include a linker portion or other sections as well. Suitable fusion proteins are also those predicted to have the same effect as human relaxin in vivo, based, for example, on structural modeling. The fusion protein is useful in the treatment of a number of diseases and conditions, including heart disease, vascular disease, wound healing, fibrosis, fibromyalgia, and promoting angiogenesis. | 2011-10-13 |
20110250216 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS - Methods of killing prostate-specific membrane antigen (PSMA)-expressing, taxane-resistant cancer cells are provided. In particular, PSMA-expressing, taxane-resistant cancer cells are contacted with an antibody-drug conjugate (ADC) that comprises an antibody or antigen-binding fragment thereof that specifically binds to PSMA conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine. | 2011-10-13 |
20110250217 | METHODS AND COMPOSITIONS FOR ELICITING AN AMYLOID-SELECTIVE IMMUNE RESPONSE - The present invention involves methods and compositions for treating, preventing, and diagnosing amyloid-associated diseases and conditions, as well as methods and compositions for making antigens that elicit antibodies which selectively or specifically bind amyloid prefibrillar oligomers or protofibrillar aggregates over monomers or fibrils of the same amyloid. | 2011-10-13 |
20110250218 | Disease-Associated Antigens and Methods of Use Thereof - The present disclosure provides synthetic antibodies specific for a disease-associated antigen, and methods of using the antibodies in disease therapy. The present disclosure further provides diagnostic assays involving detecting the presence and/or level in biological sample of an antibody specific for a disease-associated antigen. | 2011-10-13 |
20110250219 | EPITOPE PEPTIDES DERIVED FROM VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 AND VACCINES CONTAINING THESE PEPTIDES - The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines. | 2011-10-13 |
20110250220 | MODIFIED GP140 ENVELOPE POLYPEPTIDES OF HIV-1 ISOLATES, COMPOSITIONS, STABILIZED TRIMERIC COMPLEXES, AND USES THEREOF - This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding such a polypeptide, vectors, host cells, trimeric complexes and compositions thereof. Also provided are antibodies generated against the modified polypeptides and trimeric complexes, and methods of using the modified polypeptides, compositions and trimeric complexes. | 2011-10-13 |
20110250221 | Group A Streptococcus Pharmaceutical Compositions and Methods Thereof - Isolated proteins and immunogenic fragments thereof, for use in the treatment and prevention of a Group A | 2011-10-13 |